Quick Facts

• Myoclonus: May be used as an add-on treatment for involuntary muscle spasms of cortical origin.
• Vertigo/Dizziness: Can be utilized in the management of certain forms of dizziness.
• Dyslexia: May offer a supporting role for improving specific reading skills in children.

---

What Луцетам Treats: Main Uses and Benefits

Луцетам, which contains the active substance piracetam, is a prescription medicine in several countries, particularly in Europe, for conditions where it may provide a beneficial effect on function. It is important to note that the substance has not been approved for medical use in all jurisdictions.

Approved medical uses for the substance in certain regions focus on distinct therapeutic domains:

• Cortical Myoclonus: The medication is established in the management of myoclonus, a disorder characterized by sudden, involuntary muscle jerks that originate in the cerebral cortex. It is typically administered as an adjunctive treatment alongside other standard therapies.
• Vertigo: It is used to help manage the symptoms associated with certain types of vertigo (dizziness).
• Dyslexia in Children: The substance has been observed to provide support for enhancing certain reading skills in children diagnosed with dyslexia, utilized within a comprehensive and established approach to treatment.

This medication is solely intended for use under the guidance of a qualified healthcare professional, who determines its appropriate application based on individual health needs and the relevant regional approvals.

Eligibility Profile: Official Regulatory Information

This section outlines who can and cannot use Луцетам (Piracetam) based strictly on governmental regulatory documents, such as the Summary of Product Characteristics (SmPC) provided by authorizing bodies.

Contraindicated Populations	Specific Condition/Restriction
Hypersensitivity to Piracetam or other pyrrolidone derivatives	Absolute prohibition
Patients with Cerebral Hemorrhage	Absolute prohibition
Patients with End-Stage Renal Disease (Creatinine Clearance <20 ml/min)	Absolute prohibition
Patients suffering from Huntington's Chorea	Absolute prohibition

Restrictions and Special Considerations

• Renal Function: Use is prohibited in end-stage renal disease. For patients with mild or moderate renal impairment, dose adjustment is required, and regular monitoring of creatinine clearance is necessary, particularly in the elderly on long-term treatment.
• Hemorrhage Risk: Caution is recommended in patients with severe hemorrhage, those undergoing major surgery, or those with underlying disorders of hemostasis, due to the drug's effect on platelet aggregation.
• Pregnancy and Lactation: Use is not recommended during pregnancy unless the clinical condition of the mother requires treatment and the benefit clearly outweighs potential risks. The medicine is excreted in breast milk, and therefore, use during lactation is generally not recommended.
• Age: Use in the pediatric population (children under 18 years of age) is typically not established or recommended by regulatory documentation.

Interactions with other medicines and products

When co-administered with other medicinal products, the potential for interactions must be considered. Piracetam (Луцетам) is known to primarily affect other agents through pharmacodynamic mechanisms.

Interacting Product Category	Observed Interaction and Clinical Management
Oral Anticoagulants (e.g., Acenocoumarol)	There is a potential for piracetam to enhance the effect of oral anticoagulants, leading to an increased risk of bleeding. This effect can result in a more pronounced decrease in prothrombin time/INR (International Normalized Ratio) in some patients. Frequent monitoring of prothrombin time is necessary and the dose of the anticoagulant may require adjustment.
Thyroid Hormones (T3 and T4)	Concomitant use with thyroid hormone preparations has been reported to cause symptoms such as confusion, irritability, and sleep disturbances. Caution is advised when combining these agents.
Central Nervous System (CNS) Agents	Additive effects on the central nervous system should be considered when piracetam is administered with other agents that affect the CNS, such as psychostimulants or tranquilizers.
Antiepileptic Drugs	While animal studies suggest piracetam may enhance the anticonvulsant effect of conventional antiepileptics (e.g., carbamazepine, diazepam), human pharmacokinetic studies have generally shown no significant change in the plasma levels of these common anti-seizure medications. Piracetam is often used as an adjunct in epilepsy management.

Cellular Mechanism and Pharmacodynamics

Луцетам ( Piracetam) functions primarily as a physico-chemical modulator by integrating into the phospholipid bilayer of neuronal and vascular cell membranes. This interaction modifies the membrane's fluidity and integrity, particularly in compromised cells, which directly influences the functional efficiency of embedded proteins, channels, and receptors. This foundational action leads to the modulation of key signaling pathways, specifically facilitating the release and functional efficacy of neurotransmitters, including Acetylcholine and Glutamate, thereby supporting the molecular processes of synaptic plasticity.

The drug further influences cellular bioenergetics by supporting the optimal utilization of glucose and oxygen, which contributes to the maintenance of cellular integrity under metabolic stress. Additionally, it acts on blood cell membranes, promoting the physical deformability of red blood cells and moderating platelet aggregation. This mechanical action optimizes the flow properties of blood, facilitating flow dynamics within the cerebral microvasculature.

The administration of Piracetam is achieved through either the oral route (film-coated tablets or oral solution) or the intravenous (IV) route via injection or infusion. The total daily dosage is typically divided into two or three sub-doses, and oral forms may be taken with or without food.

Official Dosing and Titration

Official dosing schedules are defined by the condition. For managing cortical myoclonus, the daily dosage begins at 7.2 g and is gradually increased by 4.8 g every three to four days, up to a maximum daily dose of 24 g. For other approved uses, such as vertigo, the dosage range is commonly 2.4 g to 4.8 g daily. For pediatric use in specific contexts (children 8 years), the dose is defined at approximately 3.2 g daily.

Procedural Adjustments

A critical procedural condition is the adjustment of the dose based on renal function, as the substance is primarily eliminated by the kidneys. The dose must be individualized according to the patient's Creatinine Clearance (CLcr). For instance, severe renal impairment (CLcr < 30 ml/min) necessitates a reduction to 1/6 of the usual daily dose, administered as a single intake. Treatment must never be discontinued abruptly; the official protocol requires a slow taper, reducing the dose by 1.2 g every two to four days to prevent procedural risks.

Evidence for use in Cortical Myoclonus

The research base for this indication includes Randomized Controlled Trials (RCTs) and specialized Double-blind Crossover Studies. Piracetam was evaluated in studies exploring how symptoms change over time in adults with myoclonus of cortical origin, including specific forms like Progressive Myoclonus Epilepsy. Researchers examined a range of outcomes related to functional imbalance, such as the frequency and severity of involuntary muscle jerks, standardized motor impairment scores, and the patient's capacity for daily-life functioning.

Studies monitored patterns where measurements of motor symptoms varied across different study dose levels. Long-term open-label follow-up studies extended observation periods for up to 18 months, providing data on how patients reported their experience over an extended timeframe. The research record contains limited data concerning milder presentations.

Evidence for use in Vertigo (Dizziness)

Piracetam was studied in conditions characterized by fluctuating or episodic manifestations of vertigo, primarily through double-blind, placebo-controlled trials and comparative studies. Research highlights changes measured during the study period, with some trials reporting variability in the measurements of episode frequency and perceived imbalance when compared to placebo. Studies also show patterns related to outcomes reflecting daily functioning, and findings were mixed across different trials.

Consistency of findings is uncertain across all subgroups because the specific cause of vertigo (central versus peripheral) was heterogeneous across different trials. Follow-up durations were limited, providing little information for long-term outcomes and the durability of any observed changes.

Evidence for use in Dyslexia in Children

The evidence is derived from double-blind, placebo-controlled, multicenter studies involving school-aged children with developmental dyslexia. Research examined changes in specific reading abilities and learning performance scores. Trials reported how specific reading test scores evolved in the observed populations compared to the placebo groups during the study period. Findings indicate that changes were sometimes observed in certain reading parameters, though this pattern was not consistent across all literacy measures.

Research provides context regarding short-term changes, but there is limited information for long-term outcomes, as follow-up durations were typically short-to-medium term. The results apply only to the populations studied, which were carefully selected children with specific profiles of reading difficulties.

What is Still Uncertain in the Research Record

The research base for age-related cognitive impairment is limited, with many studies being older and may not align with current research standards. Findings in older adults with non-dementia cognitive impairment have been heterogeneous. Although meta-analyses reported an association between the study group and a change in the Clinical Global Impression of Change (CGIC) ratings, these results were often inconsistent with objective cognitive test scores.

A key limitation across all indications is the heterogeneity of the patient populations and the limited information for long-term outcomes. Research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes. Finally, the research record provides insufficient evidence for its study or application in patients with major neurodegenerative dementias.

Key Studies & References

1. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis

Common questions about Луцетам (FAQ)

---

Q: Can children take Луцетам?

The official product information specifies the use of this medicine for the treatment of dyslexia in children, when used as an adjunct to speech therapy. This indication typically applies to a certain age range. Use for other conditions in the pediatric population is generally noted as not established in regulatory documents.

Q: Is it normal to feel a bit restless when starting Луцетам?

Official regulatory documents list hyperkinesia, which involves increased or restless movement, as a possible side effect of the medicine. Other reports from surveillance mention agitation, although the exact frequency of these reactions is often not specified.

Q: Does Луцетам cause any changes in mood or sleep patterns?

Official documentation indicates that changes in mood and sleep patterns are possible. Side effects listed include nervousness (common), depression, and somnolence (drowsiness), categorized as uncommon. Other effects such as anxiety, agitation, and insomnia have also been reported through post-marketing surveillance.

Q: What if I experience unusual anxiety after starting Луцетам?

Anxiety is listed in the official product information as one of the possible side effects associated with this medicine. It is categorized as a reported, undesirable effect.

Q: Does Луцетам cause weight gain or weight loss?

According to the official regulatory documents, weight gain is listed as a common undesirable effect of the medicine. Weight loss is not listed among the commonly or uncommonly reported side effects in the official safety profile.

Q: Can older adults use Луцетам safely?

The official guidance notes that the medicine can be used by older adults, but with specific procedural requirements. For those receiving long-term treatment, regular evaluation of kidney function (creatinine clearance) is required to allow for potential dose adjustments.

Q: Does Луцетам cause fatigue?

Regulatory documents list the clinical terms somnolence (drowsiness) and asthenia (weakness) as uncommon side effects. These are the clinical descriptions provided on the label that may relate to a feeling of general fatigue.

Q: Does taking Луцетам affect my ability to drive or operate machinery?

Official product information states that an influence on the ability to drive and use machines is possible due to the various reported adverse reactions. The official label indicates this possibility is a factor that must be taken into account.

Q: What should I do if I miss a dose of Луцетам?

Standard patient information advises that if a dose is missed, it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. Taking two doses at the same time to compensate for a forgotten dose is not advised.

Q: Is it safe to drink alcohol while taking Луцетам?

Regarding the drug's physical effects, studies have indicated that taking the medicine does not appear to change the plasma levels of alcohol, and alcohol similarly does not affect the levels of the medicine in the body.

Q: What specific conditions is Луцетам approved to treat in my region?

The specific conditions for which this medicine is approved can vary depending on the country or region of use. However, common therapeutic indications listed in international regulatory summaries include cortical myoclonus, vertigo, and dyslexia (as an adjunct to speech therapy).

Q: Is there a generic version of Луцетам available?

The medicine contains the active ingredient piracetam, which is a generic chemical compound. Due to its status, the substance is marketed globally under many different brand names.

Q: How long can a person safely stay on a treatment course of Луцетам?

The duration of treatment is determined on a case-by-case basis and depends on the specific condition being addressed. Official guidance sometimes includes procedural rules; for example, in the case of cortical myoclonus, the label suggests attempting to decrease or discontinue the medicine every six months to manage treatment.

Q: Is Луцетам a controlled substance or prescription-only?

The legal status and regulatory classification of the active ingredient piracetam varies significantly depending on the country or region. In some areas, it is strictly classified as a prescription-only medicine, while in others it may be considered an uncontrolled substance.

Q: Does taking too much Луцетам cause an overdose?

Official regulatory documents have examined cases of high single-dose intake. The documents report that no additional adverse reactions specifically related to overdose have been recorded following the oral intake of a large amount of the medicine.

Q: Are there certain foods I should avoid while taking Луцетам?

The official instructions state that the medicine can be taken either with food or without it. No specific foods are listed in the regulatory documents that must be strictly avoided when using the medicine.

Q: What is the difference between different strengths of Луцетам tablets?

Different tablet strengths, such as 800 mg or 1200 mg formulations, are provided to allow for flexibility when achieving the total daily dosage recommended for a specific condition. The required total daily amount varies significantly based on the approved use.

Q: Is Луцетам used for memory enhancement in healthy people?

Official regulatory documentation lists approved indications for the medicine in the context of treating conditions involving impairment or disease, such as cortical myoclonus or dyslexia. It is not approved for the purpose of general memory enhancement or cognitive improvement in healthy individuals.

Q: Are there different brand names for the same active ingredient as Луцетам?

Yes, the active substance in this medicine is piracetam, which is sold under many different brand names across the globe. Some examples include Nootropil, Neurocetam, and Normabrain.

Q: Does official documentation specify how long the treatment typically lasts?

Official documents sometimes specify treatment durations that are dependent on the approved condition. For example, in the management of vertigo, a treatment duration of 8 weeks has been indicated in some regulatory information.

Q: Is Луцетам safe to take with anti-depressants?

The official medicine label advises caution when the medicine is used with other Central Nervous System (CNS) agents, which includes many types of anti-depressants. This is noted due to the potential for additive effects between the two substances.

Q: Is the drug approved by major international health bodies like the FDA or EMA?

The regulatory status of this medicine varies significantly. The drug is not approved for any medical use by the U.S. FDA, but it is approved and regulated by various health bodies in Europe (which generally align with EMA standards) and other international regions.

The storage and disposal of Луцетам (Piracetam) must comply with the conditions specified in official regulatory labeling to ensure product integrity and environmental safety.

Official Storage Conditions

Requirement	Regulatory Statement
Temperature	Store at a temperature below 25°C or below 30°C (varies by product and region).
Protection	Keep in the original container and protect from moisture.
Stability	Do not use the medicine after the expiry date (EXP) printed on the packaging.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Official protocol prohibits discarding expired or unused Луцетам via wastewater or routine household waste. To properly dispose of the medicine and help protect the environment, patients must consult a pharmacist or utilize local pharmaceutical collection programs.